Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug3910 | less-frequency hemodialysis Wiki | 0.45 |
drug3819 | dialysis Wiki | 0.45 |
drug1168 | Electronic survey Wiki | 0.45 |
Name (Synonyms) | Correlation | |
---|---|---|
D007674 | Kidney Diseases NIH | 0.40 |
D003324 | Coronary Artery Disease NIH | 0.22 |
D029424 | Pulmonary Disease, Chronic Obstructive NIH | 0.17 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0000077 | Abnormality of the kidney HPO | 0.45 |
HP:0001677 | Coronary artery atherosclerosis HPO | 0.22 |
HP:0006510 | Chronic pulmonary obstruction HPO | 0.18 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0006536 | Pulmonary obstruction HPO | 0.17 |
HP:0001297 | Stroke HPO | 0.12 |
HP:0002664 | Neoplasm HPO | 0.08 |
Navigate: Correlations HPO
There are 5 clinical trials
This phase III trial compares the effect of adding tocilizumab to standard of care versus standard of care alone in treating cytokine release syndrome (CRS) in patients with SARS-CoV-2 infection. CRS is a potentially serious disorder caused by the release of an excessive amount of substance that is made by cells of the immune system (cytokines) as a response to viral infection. Tocilizumab is used to decrease the body's immune response. Adding tocilizumab to standard of care may work better in treating CRS in patients with SARS-CoV-2 infection compared to standard of care alone.
Description: The 7-day length of invasive MV for each arm will be estimated with 95% confidence intervals (CIs) using the exact binomial distribution. Their difference by the arms will be tested by Cochran-Mantel-Haenszel (CMH) test stratified by the age group and Sequential Organ Failure Assessment (SOFA) score at significance level of 0.05.
Measure: 7-day length of invasive mechanical ventilation (MV) Time: Up to 7 daysDescription: Defined as death within 30-day after randomization. The 30-day mortality rate for each arm will be estimated with 95% CIs using the exact binomial distribution. Their difference by the arms will be tested CMH test stratified by the age group and SOFA score at significance level of 0.05.
Measure: 30-day mortality rate Time: Up to 30-day after randomizationDescription: The rate of ICU transfer for each arm will be estimated with 95% CIs using the exact binomial distribution. Their difference by the arms will be tested CMH test stratified by the age group and SOFA score at significance level of 0.05.
Measure: Rate of intensive care (ICU) transfer Time: Up to 2 yearsDescription: The rate of invasive mechanical ventilation for each arm will be estimated with 95% CIs using the exact binomial distribution. Their difference by the arms will be tested CMH test stratified by the age group and SOFA score at significance level of 0.05.
Measure: Rate of invasive mechanical ventilation Time: Up to 2 yearsDescription: The rate of tracheostomy for each arm will be estimated with 95% CIs using the exact binomial distribution. Their difference by the arms will be tested CMH test stratified by the age group and SOFA score at significance level of 0.05.
Measure: Rate of tracheostomy Time: Up to 2 yearsDescription: Will first be described by median and inter-quartile, and then compared between two arms by Wilcoxon Sum-Rank test
Measure: Length of ICU stay Time: Up to 2 yearsFacing the unusual situation imposed by the coronavirus disease, the aim of this study is to evaluate the risk and effects of less frequent hemodialysis on prevalent patients
Description: Time to all-cause and cardiovascular death
Measure: Mortality Time: From date of beginning of the study until the date of death assessed up to 52 weeksDescription: Time variation of the biological parameters mentioned in the title. Repeated measurements of laboratory variables will be averaged into patient quarterly means to minimize measurement variability.
Measure: Anemia, Nutrition, Adequation of dialysis, total ultrafiltration, ultrafiltration rate, Time: From date of beginning of the study assessed up to 52 weeksDescription: Time to first hospitalization of any cause
Measure: Hospitalization Time: From date of beginning of the study until the date of first hospitalization assessed up to 52 weeksDescription: Time to first endovascular or quirurgical intervention of the vascular access utilized at the start of the study
Measure: Vascular Access Time: From date of beginning of the study until the date of first intervention assessed up to 52 weeksStarting in late 2019, the world is facing a pandemic with the SARS-CoV-2 virus. Patients with end-stage kidney disease and on treatment with renal replacement therapy are high risk patients, as they are unable to maximize social distancing. We plan to gather epidemiological data using two different diagnostic approaches. We will compare a symptom-driven screening, in combination with a nasopharyngeal swab plus computed tomography (clinical approach) against serological surveillance.
Description: serology to test for IgG and IgM antibodies against SARS-CoV-2
Measure: Antibodies against SARS-CoV-2 Time: one yearTo understand the impact of COVID-19 restrictions on the wellbeing, quality of life and physical activity of people with end-stage renal disease, currently dialysing in-centre versus at home in the UK and their experience of telemedicine.
Description: Participants will be asked during a qualitative interview about the effect of COVID-19 restrictions on their; well-being, quality of life and physical activity and sedentary behaviours
Measure: Qualitative assessment of the effect of COVID-19 restrictions on patients' well-being, quality of life and physical activity and sedentary behaviours Time: Day 1Description: Participants will be asked during a qualitative interview about their perceptions and experiences of telemedicine
Measure: Thematic analysis of qualitative interview exploring patients' experiences of telemedicine during the COVID-19 restrictions in the UK Time: Day 1The purpose of this study is to collect genomic and clinical data among a cohort of hemodialysis patients and analyze the association between genetic markers and the development and severity of illness in response to SARS-CoV-2.
Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports